BridgeBio Pharma (BBIO) Other Non-Current Assets (2018 - 2026)

BridgeBio Pharma has reported Other Non-Current Assets for 9 years, with the latest figure at $18.6 million in Q1 2026.

• Quarterly Other Non-Current Assets rose 12.11% year-over-year to $18.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.6 million (up 12.11% YoY) and the FY2025 annual result came in at $16.7 million, down 8.15% from the prior year.
• Other Non-Current Assets rose to $18.6 million in Q1 2026 per BBIO's latest filing, from $16.7 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $35.3 million in Q1 2022 and troughed at $16.6 million in Q1 2025.
• A 5-year average of $21.9 million and a median of $20.3 million in 2024 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets slumped 41.21% in 2023, then advanced 25.78% in 2025.
• Over 5 years, Other Non-Current Assets stood at $20.2 million in 2022, then advanced by 11.87% to $22.6 million in 2023, then fell by 19.58% to $18.2 million in 2024, then decreased by 8.15% to $16.7 million in 2025, then rose by 11.42% to $18.6 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $18.6 million, $16.7 million, and $25.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.